Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Vet clinics for licensure, compounding transparency, sterile technique, and follow-up protocols
The rationale is mechanistic non-overlap: rather than two compounds acting through the same pathway with redundant effects, BPC-157 and TB-500 engage distinct targets the former operating through nitric-oxide-pathway and VEGFR2 modulation, the latter through actin-cytoskeleton regulation
Composition BPC-157: 10 mg Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Peptide identity and purity assessment via HPLC/LC-MS Assay development and calibration for quantitative analysis Chromatographic method optimization for impurity profiling Stability characterization of a lyophilized peptide under laboratory storage conditions Documentation Lot-specific COA available (HPLC/LC-MS) Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Manufactured in the USA in an ISO 9001based, cGMP-aligned facility Lot-specific COA (HPLC/LC-MS) with verification key Third-party verification link provided per lot (Janoshik) Lyophilized for transit stability
When stored correctly, a vial can last until the expiration date, keeping its full potency
S., Madi, K., Nunes, T., & Zaltman, C
147 published a randomized trial in which the melatonin/hypothermia group, at 5 days of life, had fewer seizures and fewer white matter abnormalities on MRI
